SCHEMBL4926751

SCHEMBL4926751

Cc1oc(-c2ccc(C(C)C)cc2)nc1COCCl

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.42
PPARA Q07869 7/20 0.42
HSD17B10 Q99714 2/20 0.41
RAB9A P51151 3/20 0.40
PPARD Q03181 1/20 0.40
NPC1 O15118 2/20 0.39
KDM4E B2RXH2 2/20 0.39
KDR P35968 1/20 0.39
TARBP2 Q15633 1/20 0.38
NOTUM Q6P988 2/20 0.38
POLB P06746 1/20 0.37
FFAR1 O14842 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4355153 0.84 KDM4E (0.43) PPARGPPARAHSD17B10RAB9APPARD
SCHEMBL4929598 0.83 KDM4E (0.56) PPARGPPARARAB9APPARDNPC1
SCHEMBL4924238 0.80 ALDH1A1 (0.47) PPARGPPARAHSD17B10KDM4EKDR
SCHEMBL17047874 0.79 ALDH1A1 (0.43) PPARGPPARARAB9ANPC1KDM4E
SCHEMBL1051790 0.79 NOTUM (0.45) PPARGPPARAHSD17B10RAB9APPARD
SCHEMBL6293022 0.76 RAB9A (0.50) PPARGPPARAHSD17B10RAB9APPARD
SCHEMBL6293021 0.74 KDM4E (0.52) PPARGPPARAHSD17B10PPARDKDM4E
SCHEMBL5760607 0.72 PPARG (0.51) PPARGPPARAKDRPOLBFFAR1
SCHEMBL6289197 0.72 PPARG (0.51) PPARGPPARARAB9APPARDNPC1
SCHEMBL4928762 0.71 PPARG (0.43) PPARGPPARAHSD17B10RAB9APPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100439345-C (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexylmethoxy acetic acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis. SANNOFFE AVENTIS PHARMA GMBH (DE) 2008-12-03 CN disclosed
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-01-17 US disclosed
US-7259177-B2 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-21 US disclosed
CN-1753879-A 3- (2-phenyl-oxazol-4-ylmethoxy) cyclohexyl methoxyacetic acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis SANNOFFE AVENTIS PHARMA GMBH (DE) 2006-03-29 CN disclosed
US-20050101637-A1 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015238-A1 CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS GPR119, PC, ACADM PPARG 80/4885PPARA 122/4885HSD17B10 90/4885
US-20050101637-A1 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals GPR119, PC, CPT1A PPARG 99/4885PPARA 132/4885HSD17B10 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.